




Enriching future liver remnant assessment



Key Features

- ⦿ Assessment of liver tissue health with validated metrics.¹⁻⁴
- ⦿ Automatic liver segmentation and volumetry to facilitate FLR estimation.⁵
- ⦿ Supports identification of patients at risk of poor post-operative outcomes.^{6,7}
- ⦿ Service is reimbursed by CMS and covered by many commercial payers.
- ⦿ Delivered through a cloud-based service, needing no additional MRI infrastructure.

Hepatica Details








- ⦿ Hepatica is cleared for commercial use in the U.S. under FDA 510(k).
- ⦿ Appropriate CPT Codes billed for the Hepatica service: 0648T and +0649T.

**Hepatica
uses MRI to provide
quantitative assessment of
liver health and volume
to support better surgical
decision-making and
clinical outcomes.**



Case study: Hepatica enhances pre-surgical decision-making for patients with liver cancer

- 80-year-old female patient with colorectal metastases, originally considered for a right hepatectomy.
- Hepatica indicated evidence of liver disease activity and elevated liver fat (cT1 = 841 ms and PDFF = 26%) with a FLR volume of only 33%.
- DVE was performed to induce hypertrophy in the left lobe to improve FLR.
- Seven weeks later, Hepatica showed improved liver health (cT1 = 729 ms and PDFF = 13%) and FLR volume increased to 46%, giving the surgeon the confidence to proceed with the resection.
- The patient underwent uneventful surgery and recovered well after four days in hospital.

Hepatica 	Pre-DVE	Post-DVE
Disease activity Normal reference range: cT1 < 800 ms	cT1 = 841 ms 	cT1 = 729 ms 
Fat Normal reference range: PDFF < 5%	PDFF = 26% 	PDFF = 13% 
3D volume		
FLR*	33%	46%

*Note that Hepatica supports clinical estimation of FLR volume through reported Couinaud segment volumes. FLR for the planned right hepatectomy was calculated from the volumes in segments 1, 2, 3, 4a, and 4b provided in the Hepatica report.

Abbreviations: cT1: corrected T1, PDFF: proton density fat fraction, FLR: future liver remnant, DVE: dual vein embolization.

References

1. Banerjee, R., et al. (2014). Journal of Hepatology, 60(1), 69-77.
2. Jayaswal, A., et al. (2020). Liver International, 40(12), 3071-3082.
3. Andersson, A., et al. (2021). Clinical Gastroenterology and Hepatology. Advance online publication.
4. Beyer, C., et al. (2021). PloS One, 16(4), e0249491.
5. Mojtahed, A., et al. (2021). Abdominal Radiology, 44(1), 72-84.
6. Mole, D. J., et al. (2020). PloS One, 15(12), e0238568.
7. Sethi, P., et al. (2021). BJR Case Reports, 7(3), 20200172.